Comparative Pharmacology
Head-to-head clinical analysis: HAILEY 1 5 30 versus VOLNEA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HAILEY 1 5 30 versus VOLNEA.
HAILEY 1.5/30 vs VOLNEA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and desogestrel. Ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; desogestrel, a progestin, inhibits ovulation and alters cervical mucus and endometrial receptivity.
Volnea is a combination of dienogest and ethinylestradiol. Dienogest is a progestin with antiandrogenic activity, and ethinylestradiol is an estrogen. The contraceptive effect is achieved through suppression of gonadotropins (FSH and LH), inhibition of ovulation, and changes in cervical mucus and endometrium.
One tablet (ethinyl estradiol 0.03 mg, levonorgestrel 0.15 mg) orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. For continuous cycling, may take active tablets daily without placebo.
One tablet (0.02 mg ethinylestradiol + 3 mg drospirenone) orally once daily for 21 consecutive days, followed by a 7-day hormone-free interval.
None Documented
None Documented
Terminal elimination half-life of ethinyl estradiol is 13-27 hours (mean 17 hours); for norgestimate, active metabolite norelgestromin has half-life 12-30 hours (mean 19 hours). Steady state reached after 7-14 days.
Terminal half-life: 12 hours (range 10-14 h). Supports twice-daily dosing in patients with normal renal function.
Approximately 40% renal (as metabolites), 32% fecal (as metabolites), and <1% unchanged in urine.
Renal: 70% unchanged; fecal: 30% (biliary elimination)
Category C
Category C
Oral Contraceptive
Oral Contraceptive